Fig. 4: Effectiveness of mRNA vaccines against any symptomatic SARS-CoV-2 Omicron infection regardless of subvariant and against severe COVID-19.
From: Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar
Effectiveness of the BNT162b2 and mRNA-1273 vaccines against any symptomatic SARS-CoV-2 Omicron infection regardless of subvariant (panels a and b, respectively) and against any severe9, critical9, or fatal10 COVID-19 due to an Omicron infection (c, d, respectively). a Includes 39,855 and 23,814 biologically independent samples for cases and controls, respectively, (b) includes 21,810 and 13,288 biologically independent samples for cases and controls, respectively, (c) includes 268 and 692 biologically independent samples for cases and controls, respectively, and (d) includes 164 and 404 biologically independent samples for cases and controls, respectively. Data are presented as effectiveness point estimates. Error bars indicate the corresponding 95% confidence intervals.
